Duloxetine for Colorectal Cancer
Trial Summary
What is the purpose of this trial?
This phase II/III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount of certain chemicals in the brain that help relieve depression and pain. Giving duloxetine in patients undergoing treatment with oxaliplatin for colorectal cancer may help prevent peripheral neuropathy.
Will I have to stop taking my current medications?
Yes, you may need to stop taking certain medications. You cannot use other drugs for peripheral neuropathy, certain antidepressants, or serotonin-altering agents. Some medications must be stopped at least 7 to 14 days before starting the trial.
What safety data exists for Duloxetine in humans?
How does the drug Duloxetine differ from other treatments for colorectal cancer?
Duloxetine is primarily known as an antidepressant and is not a standard treatment for colorectal cancer. Its use in this context is unique and experimental, potentially exploring its effects on cancer-related symptoms or side effects rather than directly targeting cancer cells like traditional chemotherapy drugs.678910
Research Team
Ellen M. Lavoie Smith, PhD
Principal Investigator
The University of Alabama at Birmingham School of Nursing
Eligibility Criteria
This trial is for stage II-III colorectal cancer patients who are about to receive oxaliplatin treatment and have no prior neurotoxic chemotherapy, pre-existing neuropathy, seizure disorders, glaucoma, severe psychiatric conditions or substance abuse. They must not be on certain medications like MAOIs or strong CYP1A2 inhibitors and should not be pregnant.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive duloxetine or placebo alongside standard oxaliplatin treatment to prevent peripheral neuropathy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Duloxetine
Find a Clinic Near You
Who Is Running the Clinical Trial?
Alliance for Clinical Trials in Oncology
Lead Sponsor
National Cancer Institute (NCI)
Collaborator